Roche Bi-Specific Antibody Has Eylea In Its Sights After Lucentis Win
Following the failure late last year of Regeneron's combination of Eylea with nesvacumab, a Phase II success for the Swiss major's RG7716 is a boost for the theory that a VEGF/Ang-2 combo therapy can transform the treatment of certain eye diseases.
You may also be interested in...
Roche unveiled positive results from the Phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD).
Emerging Company Profile: Inhibitors of VEGF-A alternative mRNA splicing could deliver a step-change in the treatment of retinal eye diseases, hopes UK start-up Exonate.
The market slump at the beginning of February affected virtually all of the stocks of the top 50 pharmaceutical companies. But unpredicted clinical successes or surprisingly good financials still kept a few companies above water.